The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG).
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2012
At a glance
- Drugs Acadesine (Primary)
- Indications Cardiovascular disorders; Cerebrovascular disorders; Coronary disorders; Embolism and thrombosis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms RED-CABG
- Sponsors Merck & Co; Schering-Plough
- 21 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Aug 2010 Planned end date changed from 1 Oct 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.